• Skip to main content
  • Main Menu
  • Navigation for access to support pages
  • Navigation for access to legal pages
 Logo Viva Technology
  • Session Recordings
  • Speakers
  • Exhibitors
  • FAQ
  • General Public Day
  • confirmation_numberGet Your 2026 Pass
  • Become an Exhibitor
 Viva Technology

17-20 June 2026

Paris Expo Porte de Versailles

1 Place de la Porte de Versailles

F-75015 Paris France

More Infoarrow_right_alt

Event organizers

2025 ThemesConference ProgramOur Speakers

Exhibitors at VivaTech2025 Partners

Startups at VivaTechInvestors at VivaTech2025 Startup Challenges and Awards

JournalistsMedia Partners2025 PresskitPress Releases

About UsOur CommitmentsGeneral Public DayPractical Information

©Viva Technology 2016-2025 all rights reserved

Site MapSite noticeWebsite terms & conditionsB2B terms & conditionsData Privacy
  1.  Logo Viva Technology
  2. Speakers
  3. Nina Mian
 Photo Nina Mian

Nina Mian

Executive Director

AstraZeneca

#
Artificial Intelligence
Healthcare & Wellness

About Me

Nina is Executive Director and Head of Data Science & Advanced Analytics at AstraZeneca. She is proud to lead an exceptional multidisciplinary team dedicated to leveraging data science to drive strategic decision-making and innovation. Under Nina's leadership, the team has successfully implemented data-driven initiatives that have significantly improved operational efficiency and scientific impact, accelerating the delivery of life-changing medicines to patients. She is energized by ambitious challenges that push the boundaries of what is technically and organizationally possible, while creating a clear path to meaningful impact. Her career spans across areas including bioinformatics, knowledge engineering, real-world evidence, and learning & development. She has also held positions that foster innovation and support start-ups. Nina holds degrees in Biochemistry, Bioinformatics, and a MBA from Manchester Business School, UK.

Hear My Insights

AI-Powered Drug Innovation: From Discovery to Development

AI-Powered Drug Innovation: From Discovery to Development The traditional journey of drug discovery and development is long, expensive, and fraught with uncertainty. Today, artificial intelligence is transforming this paradigm, offering the potential to significantly compress timelines across the entire spectrum, from initial target identification through preclinical studies and clinical trials. By enabling sophisticated modeling of biological systems and patient responses with exceptional precision, AI is not only accelerating the identification of promising drug candidates but also optimizing their development pathways. This session will explore what breakthroughs are already reshaping the field—and which are just around the corner. What are the strategic and regulatory hurdles to integrating these tools into an industry built on rigorous validation? And how can we harness the full promise of AI while safeguarding the trust, safety, and ethics that underpin medical innovation?